TRDA Q2 2025 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-97.9% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$47M-2402.5% margin

Net Income

-$43M-2210.4% margin

EPS (Diluted)

$-1.04

QoQ Revenue Growth

-90.5%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$449M

Total Liabilities

$69M

Stockholders' Equity

$380M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$95M	-97.9%
Gross Profit	$2M	$95M	-97.9%
Operating Income	-$47M	$53M	-187.7%
Net Income	-$43M	$55M	-178.3%

Revenue Segments

License

$900,000100%